126 related articles for article (PubMed ID: 21711150)
1. Fitness and molecular mechanisms of resistance to rifaximin in in vitro selected Escherichia coli mutants.
Pons MJ; Mensa L; Gascón J; Ruiz J
Microb Drug Resist; 2012 Aug; 18(4):376-9. PubMed ID: 21711150
[TBL] [Abstract][Full Text] [Related]
2. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.
Kothary V; Scherl EJ; Bosworth B; Jiang ZD; Dupont HL; Harel J; Simpson KW; Dogan B
Antimicrob Agents Chemother; 2013 Feb; 57(2):811-7. PubMed ID: 23183443
[TBL] [Abstract][Full Text] [Related]
3. Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.
Gill SK; Garcia GA
Tuberculosis (Edinb); 2011 Sep; 91(5):361-9. PubMed ID: 21704562
[TBL] [Abstract][Full Text] [Related]
4. In vitro development and analysis of Escherichia coli and Shigella boydii azithromycin-resistant mutants.
Gomes C; Pons MJ; Magallon-Tejada A; Durand D; Lluque A; Mosquito S; Riveros M; Mercado E; Prada A; Ochoa TJ; Ruiz J
Microb Drug Resist; 2013 Apr; 19(2):88-93. PubMed ID: 23176550
[TBL] [Abstract][Full Text] [Related]
5. Relevant role of efflux pumps in high levels of rifaximin resistance in Escherichia coli clinical isolates.
Gomes C; Ruiz L; Pons MJ; Ochoa TJ; Ruiz J
Trans R Soc Trop Med Hyg; 2013 Sep; 107(9):545-9. PubMed ID: 23843564
[TBL] [Abstract][Full Text] [Related]
6. Altered spectrum of multidrug resistance associated with a single point mutation in the Escherichia coli RND-type MDR efflux pump YhiV (MdtF).
Bohnert JA; Schuster S; Fähnrich E; Trittler R; Kern WV
J Antimicrob Chemother; 2007 Jun; 59(6):1216-22. PubMed ID: 17062614
[TBL] [Abstract][Full Text] [Related]
7. Which mechanisms of azithromycin resistance are selected when efflux pumps are inhibited?
Gomes C; Martínez-Puchol S; Durand D; Lluque A; Mosquito S; Ochoa TJ; Ruiz J
Int J Antimicrob Agents; 2013 Oct; 42(4):307-11. PubMed ID: 23871456
[TBL] [Abstract][Full Text] [Related]
8. Development and analysis of furazolidone-resistant Escherichia coli mutants.
Martínez-Puchol S; Gomes C; Pons MJ; Ruiz-Roldán L; Torrents de la Peña A; Ochoa TJ; Ruiz J
APMIS; 2015 Aug; 123(8):676-81. PubMed ID: 26011027
[TBL] [Abstract][Full Text] [Related]
9. Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability.
Ruiz J; Mensa L; Pons MJ; Vila J; Gascon J
J Antimicrob Chemother; 2008 May; 61(5):1016-9. PubMed ID: 18325895
[TBL] [Abstract][Full Text] [Related]
10. Importance of Real-Time Assays To Distinguish Multidrug Efflux Pump-Inhibiting and Outer Membrane-Destabilizing Activities in Escherichia coli.
Misra R; Morrison KD; Cho HJ; Khuu T
J Bacteriol; 2015 Aug; 197(15):2479-88. PubMed ID: 25962916
[TBL] [Abstract][Full Text] [Related]
11. MarA-mediated overexpression of the AcrAB efflux pump results in decreased susceptibility to tigecycline in Escherichia coli.
Keeney D; Ruzin A; McAleese F; Murphy E; Bradford PA
J Antimicrob Chemother; 2008 Jan; 61(1):46-53. PubMed ID: 17967850
[TBL] [Abstract][Full Text] [Related]
12. Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Escherichia coli.
Paltansing S; Tengeler AC; Kraakman ME; Claas EC; Bernards AT
Microb Drug Resist; 2013 Dec; 19(6):469-76. PubMed ID: 23909485
[TBL] [Abstract][Full Text] [Related]
13. Does mutation in gyrA and/or parC or efflux pump expression play the main role in fluoroquinolone resistance in Escherichia coli urinary tract infections?: A statistical analysis study.
Shigemura K; Tanaka K; Yamamichi F; Shirakawa T; Miyake H; Fujisawa M
Int J Antimicrob Agents; 2012 Dec; 40(6):516-20. PubMed ID: 23068598
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of rifaximin against clinical isolates of Escherichia coli and other enteropathogenic bacteria isolated from travellers returning to the UK.
Hopkins KL; Mushtaq S; Richardson JF; Doumith M; de Pinna E; Cheasty T; Wain J; Livermore DM; Woodford N
Int J Antimicrob Agents; 2014 May; 43(5):431-7. PubMed ID: 24661532
[TBL] [Abstract][Full Text] [Related]
15. Resistance in Escherichia coli: variable contribution of efflux pumps with respect to different fluoroquinolones.
Huguet A; Pensec J; Soumet C
J Appl Microbiol; 2013 May; 114(5):1294-9. PubMed ID: 23414263
[TBL] [Abstract][Full Text] [Related]
16. Azithromycin resistance levels and mechanisms in Escherichia coli.
Gomes C; Ruiz-Roldán L; Mateu J; Ochoa TJ; Ruiz J
Sci Rep; 2019 Apr; 9(1):6089. PubMed ID: 30988366
[TBL] [Abstract][Full Text] [Related]
17. Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli.
Kern WV; Steinke P; Schumacher A; Schuster S; von Baum H; Bohnert JA
J Antimicrob Chemother; 2006 Feb; 57(2):339-43. PubMed ID: 16354747
[TBL] [Abstract][Full Text] [Related]
18. Effect of NlpE overproduction on multidrug resistance in Escherichia coli.
Nishino K; Yamasaki S; Hayashi-Nishino M; Yamaguchi A
Antimicrob Agents Chemother; 2010 May; 54(5):2239-43. PubMed ID: 20211889
[TBL] [Abstract][Full Text] [Related]
19. Fluoroquinolone resistance mechanisms in urinary tract pathogenic Escherichia coli isolated during rapidly increasing fluoroquinolone consumption in a low-use country.
Christiansen N; Nielsen L; Jakobsen L; Stegger M; Hansen LH; Frimodt-Møller N
Microb Drug Resist; 2011 Sep; 17(3):395-406. PubMed ID: 21668371
[TBL] [Abstract][Full Text] [Related]
20. Contribution of efflux pumps to clarithromycin resistance in Helicobacter pylori.
Hirata K; Suzuki H; Nishizawa T; Tsugawa H; Muraoka H; Saito Y; Matsuzaki J; Hibi T
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S75-9. PubMed ID: 20586871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
